ArticlePloS one2026
Deciphering the synergistic mechanism of a novel flavonoid-antioxidant combination for asthma by combining systems pharmacology and experimental validation.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asthma is a multifaceted disorder characterized by an intricate interplay of various pathophysiological processes, including airflow obstruction, bronchial hyperresponsiveness, and underlying inflammation. This complexity encompasses a multitude of genetic, molecular, and environmental factors, making it challenging to identify effective strategies for prevention and treatment. Research into the pathogenesis and treatment of asthma continues in the pursuit of more comprehensive and targeted therapeutic approaches. The asthma pathology has been shown to be influenced by the flavonoid 7,4'- Dihydroxyflavone (74DHF), which is extracted from the herb Rhizoma Glycyrrhizae (Gancao), while taking the antioxidant ascorbic acid (VC) daily through food or supplements contributes to the treatment of asthma related to immunomodulatory regulation. However, the potential molecular or systemic mechanism of the combination of 74DHF and VC in treating asthma has yet to be fully understood, despite the demonstrated individual benefits of each compound. The present study employed a systems pharmacology strategy, combining target identification, network analysis, data integration, Gene Ontology (GO) enrichment analysis, pathway analysis, and in vitro experimental validation to uncover the synergistic pharmacological mechanisms of 74DHF-VC combination for asthma therapy. The results identified 153 and 308 targets for 74DHF and VC, 37 overlapping targets and 20 hub targets among 74DHF, VC, and asthma. Based on the GO and pathway analysis, 10 optimal common GO processes and 10 key canonical pathways were enriched, which were closely related to the combination therapy of 74DHF and VC against asthma. In addition, the in vitro experiments validated that 74DHF and VC had synergistic effects on anti-inflammation and fibrosis. The combined treatment reversed the LPS induced inflammation in macrophages and TGF-β induced cell migration and fibrosis in lung epithelial cells. The current study not only successfully explains the synergistic mechanisms underlying the efficiency of 74DHF and VC against asthma but also proposes a viable and promising strategy to fasten the process of combination treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.